Creatine's Mixed Results for Depression
Analysis based on 15 articles · First reported Jun 30, 2026 · Last updated Jul 08, 2026
The mixed findings on Creatine's efficacy for depression could lead to increased research and investment in mental health treatments, potentially boosting the biotechnology and pharmaceutical sectors. However, the lack of definitive conclusions and reported adverse effects in bipolar patients suggest that widespread clinical adoption is still distant, limiting immediate market shifts.
A systematic review published in Brain Medicine, led by Bassam Jeryous Fares and Nicholas Fabiano of the University of Ottawa, investigated whether Creatine can help treat depression. The review analyzed five randomized controlled trials conducted in South Korea, the United States, Brazil, Israel, and India, involving 238 participants. Two trials showed significant benefits when Creatine was added to escitalopram or cognitive behavioral therapy for major depressive disorder, particularly in women. However, three other trials found no effect, and two bipolar patients developed hypomania or mania while taking Creatine. Researchers emphasize that while Creatine appears safe for most, more rigorous and larger trials are needed before it can be recommended for clinical practice, highlighting it as a promising lead rather than a proven remedy.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard